Related Experiment Video

Updated: Apr 12, 2026

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1
13:15

Experimental Approaches to Study Mitochondrial Localization and Function of a Nuclear Cell Cycle Kinase, Cdk1

Published on: February 25, 2016

12.5K

CMTX1 patients' cells present genomic instability corrected by CamKII inhibitors

Saleh Mones1, Burkhardt Gess2, Benoit Bordignon3

  • 1NORT. UMR INSERM 1062, INRA 1260, Aix Marseille Université, Campus Santé La Timone, 27 boulevard Jean Moulin, Marseille, 13385 Cedex 53, France. saleh.mones@univ-amu.fr.

Orphanet Journal of Rare Diseases
|May 8, 2015
PubMed
Abstract

Insights

Fibroblasts from Charcot-Marie-Tooth type 1X (CMTX1) patients show genomic instability and poor connexon activity. Treatment with Ca2+/calmodulin-dependent protein kinase II (CamKII) inhibitors corrected these cellular defects, offering a potential therapeutic avenue.

Area of Science:

  • Cell Biology
  • Neuroscience
  • Genetics

Background:

  • Fibroblasts from CMTX1 models exhibit genomic instability and impaired connexon function.
  • Transgenic mouse models of CMTX1 display motor deficits, reversible with CamKII inhibitors.

Purpose of the Study:

  • To investigate if CMTX1 patient fibroblasts share similar cellular phenotypes observed in animal models.
  • To evaluate the therapeutic potential of CamKII inhibitors in patient-derived cells.

Main Methods:

  • Culturing fibroblasts from CMTX1 patient skin biopsies.
  • Analyzing genomic instability, connexon activity, and mitotic anomalies in patient cells.
  • Assessing the effect of CamKII inhibitors on patient fibroblast phenotype.

Main Results:

  • CMTX1 patient fibroblasts exhibit genomic instability, mitotic anomalies, and reduced connexon activity, mirroring findings in GJB1 transgenic mouse models.
  • CamKII inhibitors effectively corrected the observed cellular defects in CMTX1 patient fibroblasts.
  • Centrosome overduplication was identified as a key cellular abnormality in CMTX1 fibroblasts.

Conclusions:

  • Fibroblasts from CMTX1 patients present a distinct cellular phenotype that is amenable to correction by CamKII inhibitors.
  • This study validates a cellular model for CMTX1 and identifies CamKII inhibitors as a promising therapeutic strategy for the disease.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

13.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

3.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.2K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K